Enhanced CEA-specific Immune Responses by Tat-LLO Fusion Protein

Tat-LLO 융합 단백질에 의한 CEA 특이 항종양 면역 반응의 증가

  • Yi, Soon-Aei (Department of Microbiology and Immunology, The Catholic University of Korea) ;
  • Sohn, Hyun-Jung (Department of Microbiology and Immunology, The Catholic University of Korea) ;
  • Kim, Chang-Hyun (Department of Microbiology and Immunology, The Catholic University of Korea) ;
  • Park, Mi-Young (Department of Microbiology and Immunology, The Catholic University of Korea) ;
  • Oh, Seong-Taek (Department of Surgery, College of Medicine, The Catholic University of Korea) ;
  • Kim, Tai-Gyu (Department of Microbiology and Immunology, The Catholic University of Korea)
  • 이순애 (가톨릭대학교 의과대학 미생물학교실) ;
  • 손현정 (가톨릭대학교 의과대학 미생물학교실) ;
  • 김창현 (가톨릭대학교 의과대학 미생물학교실) ;
  • 박미영 (가톨릭대학교 의과대학 미생물학교실) ;
  • 오승택 (가톨릭대학교 의과대학 외과학교실) ;
  • 김태규 (가톨릭대학교 의과대학 미생물학교실)
  • Published : 2005.09.30

Abstract

Background: Carcinoembryonic antigen (CEA) is well-known soluble tumor marker frequently detectable in peripheral blood of carcinoma patients and considered as good target for antigen-specific immunotherapy. However, it is known that the induction of immune response to CEA is very difficult because CEA is a self-antigen expressed in fetal cells and weakly expressed in normal colorectal epithelial cells. To enhance anti-tumor immunity specific for CEA, recombinant CEA protein was modified using listeriolysin O (LLO) for endosomal lysis and trans activator of transcription (Tat) domain for transducing extracellular proteins into cytoplasm. Methods: After immunization using dendritic cells pulsed with Tat-CEA, both Tat-CEA and LLO, and both Tat-CEA and Tat-LLO, antibody titer to CEA and LLO, cytotoxic T lymphocyte activity and the frequency of IFN-${\gamma}$ producing T lymphocytes were measured. Results: Immunization using DC pulsed with both Tat-CEA and Tat-LLO protein showed the increasement of production of CEA-specific antibody in serum, cytotoxic T lymphocyte activity, the frequency of IFN-${\gamma}$ secreting T cells, compared with DC pulsed with both Tat-CEA and LLO. Furthermore the ratio of CD8+T cell to $CD4^+$ cell among CEA-specific T cells was increased in group pulsed with both Tat-CEA and Tat-LLO. Conclusion: These results suggested that DC vaccine using Tat-LLO could be used for the development of effective immunotherapy for the treatment of tumor.

Keywords

References

  1. Thompson TA, Grunert F, Zimmermann W: Carcinoemb nic antigen gene family: molecular biology and clinical spectives, J Clin Lab 5;344-366, 1991 https://doi.org/10.1002/jcla.1860050510
  2. Kass E, Schlom I. Thompson I. Guadagni F, Graziano Greiner TW: Induction of protective host immunity to cinoernbrvonic antigen (CEA), a self-antigen in CEA trans nic mice, by immunizing with a recombinant vaccinia-C virus. Cancer Res 1;59:676-683, 1999
  3. Germain RN: The biochemistry and biology of antigen sentation by MHC class I and class II molecules: impli tions for development of combination vaccines. Ann N Y Acad Sci 754;114-125, 1995 https://doi.org/10.1111/j.1749-6632.1995.tb44444.x
  4. Rubartelli A, Poggi A, Sitia R, Zocchi MR: HIV-I Tat: a p peptide for all seasons. Immunol Today 19;543-545, 1998 https://doi.org/10.1016/S0167-5699(98)01351-6
  5. Wang W, El-Deiry WS: Targeting p53 by PTD-mediated transduction, Trends Biotechnol 22;431-434, 2004 https://doi.org/10.1016/j.tibtech.2004.07.002
  6. Lety MA, Frehel C, Dubail I, Beretti TL. Kaval S, Berche Charbit A: Identification of a PEST-like motif in listeriolv o required for phazosornal escape and for virulence in L teria monocvtozenes. Mol Microbiol 39;1124-1139, 2001 https://doi.org/10.1111/j.1365-2958.2001.02281.x
  7. Giammarini C, Andreoni F, Amazliani G, Casiere A, Bar S, Magnani M: Purification and characterization of a reco binant listeriolvsin O expressed in Escherichia coli and pos diagnostic applications. J Biotechnol 109;13-20, 2004 https://doi.org/10.1016/j.jbiotec.2003.10.023
  8. Beauregard KE, Lee KD, Collier RI. Swanson TA: pH-dep dent perforation of macrophage ohazosornes by listeriolv O from Listeria monocvtooenes, J Exp Med 186:1159-1163, 1997 https://doi.org/10.1084/jem.186.7.1159
  9. Portnoy DA, Jones S: The cell biology of Listeria monocy infection (escape from a vacuole). Ann N Y Acad Sci 730; 15-25, 1994 https://doi.org/10.1111/j.1749-6632.1994.tb44235.x
  10. Cho HI, Kim HJ. Oh ST, Kim TG: In vitro induction of cinoernbrvonic antigen (CEA)-specific cytotoxic T lymp cytes by dendritic cells transduced with recombinant ade viruses. Vaccine 22;224-236, 2003 https://doi.org/10.1016/S0264-410X(03)00569-3
  11. Sewell DA, Shahabi V, Gunn GR 3rd, Pan ZK, Dominiecki ME, Paterson Y: Recombinant Listeria vaccines containing PEST sequences are potent immuneadiuvants for the tumor- associated antigen human papillomavirus-16 E7. Cancer Res 64;8821-8825, 2004 https://doi.org/10.1158/0008-5472.CAN-04-1958
  12. Giammarini C, Andreoni F, Arnaaliani G, Casiere A, Bar S, Magnani M: High-level expression of the Listeria m cvtosenes listeriolvsin O in Escherichia coli and preliminar racterization of the purified protein. Protein Expr Purif 28;78-85, 2003 https://doi.org/10.1016/S1046-5928(02)00682-4
  13. Mandal M, Lee KD: Listeriolvsin Odioosome-mediated cv solie delivery of macromolecule antigen in vivo: enhancem of antigen-specific cytotoxic T lymphocyte frequency activ and tumor protection. Biochim Biophvs Acta 1563;7-17, 2002 https://doi.org/10.1016/S0005-2736(02)00368-1
  14. Bradford MM: A rapid and sensitive method for the quant tion of microgram quantities of protein utilizing the prine of protein-dye binding. Anal Biochem 72;248-254, 1976 https://doi.org/10.1016/0003-2697(76)90527-3
  15. Lima J. Tenkins C, Guerrero A, Triozzi PL, Shaw DR, St TV: A DNA vaccine encoding genetic fusions of carcin embryonic antigen (CEA) and granulocyte/macrophage co nv-stimulatina factor (GM-CSF). Vaccine 23;1273-1283, 2005 https://doi.org/10.1016/j.vaccine.2004.08.043
  16. Boon T, Cerottini TC, Van den Evnde B, van der Bruggen Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12;337-365, 1994 https://doi.org/10.1146/annurev.iy.12.040194.002005
  17. You YH, Hefta LT, Yazaki PI. Wu AM, Shively TE: Ex ssion, purification, and characterization of a two domain cinoernbrvonic antigen minizene (N-A3) in oicbia pastoris, essential role of the N-domain. Anticancer Res 18;3193-32 1998
  18. Hellwig S, Robin F, Drossard T, Raven NP, Vacuero-Ma C, Shively TE, FischerR: Production of carcinoernbrvonic tizcn (CEA) N-A3 domain in Pichia tiastoris by fermentation. Biotechnol Appl Biochem (Pt 3) 267-275, 1999
  19. Frankel AD, Pabo CO: Cellular uptake of the tat pro from human immunodeficiency virus. Cell 55;1189-11 1988 https://doi.org/10.1016/0092-8674(88)90263-2
  20. Kim DT, Mitchell DT, Brockstedt DG, Fong L, Nolan G Fathrnan CG, Engleman EG, Rothbard TB: Introduction soluble proteins into the MHC class I pathway by coniu tion toan HIV tat peptide. J Immunol 159;1666-1668, 1997
  21. Fawell S, Seery I. Daikh Y, Moore C, Chen LL, Pepin B, Barsoum T: Tat-mediated delivery of heterologous prote into cells. Proc Natl Acad Sci USA 91;664-668, 1994
  22. Nakamura T, Tanaka T, Takagi H, Sato M: Cloning and terozeneous in vivo expression of Tat binding protein (TBP-1) inthe mouse. Biochim Biophys Acta 399;93-10 1998
  23. 안창혁, 강원경, 오승택, 조현일, 김태규: CEA와 Tat융합 단백질을 이용한 CEA 특이 항종양 면역능의 유도 증가. J Korean Soc Coloproctol 19;121-128, 2003
  24. 원은하, 김창현, 박미영, 조현일, 오승택, 홍용길, 김태규 CEA 발현 수지상세포를 이용한 CEA 특이 살해 T세포의 유도. Immune Network 3;295-301, 2003 https://doi.org/10.4110/in.2003.3.4.295
  25. Ye L, Bu Z, Skeen MT, Ziegler HK, Compans RW, Y C: Enhanced immunocenicitv of SIV Gag DNA vaccin encoding chimeric proteins containing a C-terminal segm of Listeriolvsin O. Virus Res 97;7-16, 2003 https://doi.org/10.1016/S0168-1702(03)00216-8
  26. Timmerman JM, Levy R: Dendritic cell vaccines for can immunotherapy. Annu Rev Med 50;507-529, 1999 https://doi.org/10.1146/annurev.med.50.1.507